GMED · Insider Trading
GLOBUS MEDICAL INC
Every open-market purchase and sale reported by GMED officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-05 | Ann D Rhoads | Director | Sell | −5,000 | −$425.00K |
| 2026-09-16 | James R Tobin | Director | MIXED | — | −$476.05K |
| 2026-08-19 | Stephen T Zarrilli | Director | MIXED | — | −$844.22K |
| 2026-07-28 | David D Davidar | Director | G | −2,500 | — |
| 2026-06-09 | David D Davidar | Director | MIXED | — | −$1.36M |
| 2026-06-08 | Ann D Rhoads | Director | M | +25,000 | +$656.75K |
| 2026-02-27 | Kelly Huller | EVP, GC, Corporate Secretary | MIXED | — | −$1.02M |
| 2026-02-17 | Kelly Huller | EVP, GC, Corporate Secretary | MIXED | — | −$420.30K |
| 2026-01-23 | Kelly Huller | EVP, GC, Corporate Secretary | A | +40,000 deriv. | — |
| 2026-01-23 | David D Davidar | Director | A | +15,000 deriv. | — |
| 2026-01-23 | Dan Wolterman | Director | A | +15,000 deriv. | — |
| 2026-01-23 | John A DeFord | Director | A | +15,000 deriv. | — |
| 2026-01-23 | Stephen T Zarrilli | Director | A | +15,000 deriv. | — |
| 2026-01-23 | James R Tobin | Director | A | +15,000 deriv. | — |
| 2026-01-23 | Ann D Rhoads | Director | A | +15,000 deriv. | — |
| 2026-01-23 | Dan Lemaitre | Director | A | +15,000 deriv. | — |
| 2026-01-23 | Robert Andrew Douglas | Director | A | +15,000 deriv. | — |
| 2026-01-23 | David C Paul | Executive Chairman | A | +100,000 deriv. | — |
| 2026-01-23 | Kyle Kline | Senior Vice President, CFO | A | +30,000 deriv. | — |
| 2026-01-23 | Keith W Pfeil | President, CEO | A | +100,000 deriv. | — |
| 2026-01-23 | Leslie V Norwalk | Director | A | +15,000 deriv. | — |
| 2026-01-13 | Kyle Kline | Senior Vice President, CFO | M | −4,896 deriv. | — |
| 2026-01-12 | Leslie V Norwalk | Director | Sell | −2,000 | −$202.20K |
| 2026-01-12 | Kyle Kline | Senior Vice President, CFO | MIXED | — | −$176.93K |
| 2026-01-05 | David D Davidar | Director | G | −6,100 | — |
| 2025-12-16 | Leslie V Norwalk | Director | Sell | −4,000 | −$355.40K |
| 2025-12-10 | David C Paul | Executive Chairman | M | +34,375 | +$877.25K |
| 2025-12-03 | Kyle Kline | Senior Vice President, CFO | MIXED | — | −$558.90K |
| 2025-11-28 | Kelly Huller | SVP, GC, Corporate Secretary | MIXED | — | −$480.30K |
| 2025-11-13 | Stephen T Zarrilli | Director | MIXED | — | −$1.00M |
| 2025-11-13 | David D Davidar | Director | MIXED | — | −$1.51M |
| 2025-11-10 | Ann D Rhoads | Director | Sell | −10,000 | −$818.00K |
| 2025-09-16 | Ann D Rhoads | Director | Sell | −10,000 | −$584.60K |
| 2025-08-27 | Kyle Kline | Senior Vice President, CFO | A | +20,909 deriv. | — |
| 2025-08-27 | Keith W Pfeil | President, CEO | A | +40,000 deriv. | — |
| 2025-03-28 | Stephen T Zarrilli | Director | A | +15,000 deriv. | — |
| 2025-03-28 | Dan Wolterman | Director | A | +15,000 deriv. | — |
| 2025-03-28 | James R Tobin | Director | A | +15,000 deriv. | — |
| 2025-03-28 | Daniel T Scavilla | President, CEO | A | +140,000 deriv. | — |
| 2025-03-28 | Ann D Rhoads | Director | A | +15,000 deriv. | — |
| 2025-03-28 | Keith W Pfeil | COO, CFO | A | +60,000 deriv. | — |
| 2025-03-28 | David C Paul | Executive Chairman | A | +75,000 deriv. | — |
| 2025-03-28 | Leslie V Norwalk | Director | A | +15,000 deriv. | — |
| 2025-03-28 | Dan Lemaitre | Director | A | +15,000 deriv. | — |
| 2025-03-28 | Kelly Huller | SVP, GC, Corporate Secretary | A | +40,000 deriv. | — |
| 2025-03-28 | Robert Andrew Douglas | Director | A | +15,000 deriv. | — |
| 2025-03-28 | John A DeFord | Director | A | +15,000 deriv. | — |
| 2025-03-28 | David D Davidar | Director | A | +15,000 deriv. | — |
| 2025-03-04 | Ann D Rhoads | Director | Sell | −7,500 | −$590.10K |
| 2025-01-14 | Keith W Pfeil | COO, CFO | MIXED | — | −$517.21K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David D Davidar | Director | 673,642 | $51.13M |
| Daniel T Scavilla | President, CEO | 130,000 | $9.87M |
| David C Paul | Executive Chairman | 60,417 | $4.59M |
| Ann D Rhoads | Director | 35,384 | $2.69M |
| Dan Wolterman | Director | 24,025 | $1.82M |
| Kelly Huller | EVP, GC, Corporate Secretary | 20,000 | $1.52M |
| John A DeFord | Director | 15,578 | $1.18M |
| Keith W Pfeil | President, CEO | 14,167 | $1.08M |
| Leslie V Norwalk | Director | 10,419 | $790.80K |
| Kyle Kline | Senior Vice President, CFO | 3,594 | $272.78K |
| Robert Andrew Douglas | Director | 2,005 | $152.18K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GMED quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.